ALPHA
Phase 1 Completed
50 enrolled
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693.
Phase 1 Completed
35 enrolled
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 1 Completed
35 enrolled
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Phase 1 Completed
50 enrolled
ASP8374 + Cemiplimab in Recurrent Glioma
Phase 1 Completed
14 enrolled
ELM-1
Phase 1 Completed
200 enrolled
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
Phase 1 Completed
18 enrolled
CAMPOLINA
Phase 1 Completed
35 enrolled
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Phase 1 Completed
26 enrolled
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Phase 1 Completed
26 enrolled
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Phase 1 Completed
50 enrolled
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1 Completed
8 enrolled
Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects
Phase 1 Completed
22 enrolled
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
Phase 1 Completed
95 enrolled
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Phase 1 Completed
42 enrolled 39 charts
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Phase 1 Completed
11 enrolled 16 charts
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
Phase 1 Completed
33 enrolled
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
Phase 1 Completed
37 enrolled
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
Phase 1 Completed
41 enrolled
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 1 Completed
14 enrolled
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
Phase 1 Completed
28 enrolled
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Phase 1 Completed
154 enrolled
A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
Phase 1 Completed
25 enrolled
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Phase 1 Completed
18 enrolled
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
Phase 1 Completed
24 enrolled
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Phase 1 Completed
387 enrolled 2 FDA
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Phase 1 Completed
70 enrolled
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Phase 1 Completed
68 enrolled
RaDD
Phase 1 Completed
34 enrolled
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Phase 1 Completed
3 enrolled
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Phase 1 Completed
91 enrolled
LYMRIT-37-07
Phase 1 Completed
7 enrolled 10 charts
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Phase 1 Completed
34 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Phase 1 Completed
17 enrolled
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
35 enrolled
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
Phase 1 Completed
26 enrolled 10 charts
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
Phase 1 Completed
23 enrolled
BRiM
Phase 1 Completed
11 enrolled 20 charts
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
Phase 1 Completed
43 enrolled
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Phase 1 Completed
39 enrolled
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Phase 1 Completed
37 enrolled
A Study of PLX2853 in Advanced Malignancies.
Phase 1 Completed
49 enrolled
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Phase 1 Completed
18 enrolled
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
Phase 1 Completed
26 enrolled
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Phase 1 Completed
25 enrolled
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Phase 1 Completed
32 enrolled
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
Phase 1 Completed
33 enrolled
MK-3475-013
Phase 1 Completed
197 enrolled 52 charts